TY - JOUR
T1 - Early health technology assessments in pharmacogenomics
T2 - a case example in cardiovascular drugs
AU - Geenen, Joost W.
AU - Baranova, Ekaterina V.
AU - Asselbergs, Folkert W.
AU - de Boer, Anthonius
AU - Vreman, Rick A.
AU - Palmer, Colin N. A.
AU - Maitland-van der Zee, Anke Hilse
AU - Hövels, Anke M.
AU - PREDICTION-ADR Consortium
N1 - No funding info
PY - 2017/8
Y1 - 2017/8
N2 - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.Materials & Methods: A decision tree was used.Results: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.
AB - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.Materials & Methods: A decision tree was used.Results: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.
KW - Journal article
KW - Adverse drug reactions
KW - Angioedema
KW - ACE inhibitors ACE inhibitor induced angioedema
KW - Cardiovascular drugs
KW - Cost–effectiveness
KW - Health technology assessment
KW - Pharmacogenomic test
U2 - 10.2217/pgs-2017-0063
DO - 10.2217/pgs-2017-0063
M3 - Article
C2 - 28745583
SN - 1462-2416
VL - 18
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 12
ER -
